Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Otolaryngology
Clinical Trials: Esophageal Cancer
A listing of clinical trials currently looking for volunteers to enroll in Esophageal Cancer studies. Click on the closest city to find more detailed information on a research study in your area.
Alaska
Arizona
Arkansas
California
Beverly HIlls : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Beverly HIlls : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Duarte : City of Hope Updated New
Phase 1b Trial of mFOLFOX6 and Everolimus (NSC-733504)) in Patients with Metastatic Gastroesophageal Adenocarcinoma
View More »
Alhambra : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Bakersfield : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Fullerton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Los Angeles : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Redondo Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Santa Barbara : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Santa Maria : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Santa Monica : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Colorado
Denver : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Grand Junction : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Connecticut
Torrington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Waterbury : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Florida
Englewood : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Jacksonville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Miami : University of Miami, Sylvester Comprehensive Cancer Center
Study of CryoSpray Ablation(TM)to Determine Treatment Effect, Depth of Injury, and Side Effects in the Esophagus.
Pembroke Pines : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
West Palm Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Georgia
Savannah : Memorial Health University Medical Center
Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction ACOSOG Z4051
View More »
Athens : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Atlanta : Emory University Winship Cancer Institute
Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer
Lawrenceville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Macon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Marietta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Valdosta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Idaho
Illinois
Elgin : Sherman Health
ECOG 80403 - Randomized Phase II Study of ECF-C, IC-C, or FOLFOX-C in Metastatic Esophageal and GE Junction cancer
View More »
Chicago : University of Chicago
The Effects of Sorafenib on Molecular Barrett's Esophagus Cancer
Indiana
Iowa
Cedar Rapids : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Sioux City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Kansas
Westwood : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Wichita : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Wichita : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Louisiana
Alexandria : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
View More »
Baton Rouge : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
New Orleans : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Maine
Maryland
Baltimore : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Bethesda : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Massachusetts
Boston : Dana-Farber Cancer Institute
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Boston : Massachusetts General Hospital
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Boston : Dana-Farber Cancer Institute
Prospective Analysis of Hypersensitivity Reactions to Oxaliplatin
Burlington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Springfield : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Michigan
Ann Arbor : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Detroit : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Grand Rapids : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Kalamazoo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Minnesota
Duluth : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Rochester : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
St Louis Park : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Missouri
Montana
Billings : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Billings : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Bozeman : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Nebraska
Nevada
New Jersey
New Mexico
Albuquerque : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Albuquerque : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
New York
Bronx : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
New York : Memorial Sloan-Kettering Cancer Center
Afatinib (BIBW 2992) in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer
New York : Memorial Sloan-Kettering Cancer Center
Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer
Rochester : University of Rochester
Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium
Ohio
Cincinnati : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Columbus : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Dayton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Oklahoma
Oklahoma City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Oklahoma City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Tulsa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Pennsylvania
Hershey : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
View More »
Danville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Dunmore : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Philadelphia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Philadelphia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Pittsburgh : University of Pittsburgh Cancer Institute
Phase II Study of Irinotecan and Panitumumab
South Carolina
Charleston : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Charleston : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
View More »
Charleston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Charleston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Columbia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Spartanburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Tennessee
Chattanooga : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Chattanooga : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Germantown : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Memphis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Nashville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Texas
Dallas : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Houston : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Houston : S. R. Burzynski Clinic
Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Adenocarcinoma Of The Esophagus
View More »
Corpus Christi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck
Utah
Virginia
Washington
Bellevue : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Kennewick : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Kirkland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Mount Vernon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Port Angeles : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
View More »
Seattle : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Tacoma : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Wenatchee : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
West Virginia
Wisconsin
Madison : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Marshfield : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Argentina
Rosario : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Belgium
Bruxelles : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Edegem : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Gent : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Liège : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Brazil
Porto Alegre : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Salvador : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
São Paulo : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
São Paulo : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Bulgaria
Gabrovo : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Pleven : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Varna : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Vratsa : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Canada
Ottawa : The Ottawa Hospital Regional Cancer Centre
Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer
Toronto : University Health Network (Princess Margaret & Toronto General Hospitals)
Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer
China
Lianyungang : The First People's Hospital of Lianyungang
Continuous Endostar Infusion Combined With Radiotherapy in Esophageal Cancer Patients
Colombia
Teusaquillo : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Croatia
Osijek : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Zagreb : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Estonia
Tallinn : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
France
Clermont-Ferrand : Hotel Dieu
INEC Study: Immuno-modulating Enteral Nutrition in Cancer
Germany
Aachen : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Essen : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Herne, NRW : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Leverkusen : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Muenchen : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Trier, RP : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Hungary
Budapest : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Gyor : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Nyíregyháza : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Pécs : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Szeged : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Székesfehérvár : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Ireland
Dublin : St. James's Hospital,
Trial of Enteral Nutrition Enriched With Eicosapentaenoic Acid (EPA) in Upper Gastrointestinal Cancer Surgery
Israel
Beer Sheva : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Jerusalem : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Kfar Saba : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Ramat Gan : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Tel Aviv : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Italy
Milano : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Milano : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Modena : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Potenza : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Reggio Emilia : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Rimini : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Mexico
Chihuahua : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Netherlands
Amsterdam : AMC
Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium
Poland
Gdansk : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Lodz : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Olsztyn : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Szczecin : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Warszawa : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Portugal
Aveiro : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Coimbra : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Porto : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Romania
Baia Mare : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Cluj-Napoca : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Iasi : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Onesti : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Russia
Barnaul : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Moscow : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Saint Petersburg : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Saint Petersburg : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
South Africa
Durban : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Groenkloof Pretoria : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Port Elisabeth : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Pretoria : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Spain
Barcelona : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Barcelona : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Barcelona : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Barcelona : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Barcelona : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Elche : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Madrid : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Madrid : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Madrid : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Madrid : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Madrid : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Malaga : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Sabadell : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Valencia : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Ukraine
Cherkassy : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Chernivtsiy : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Dnepropetrovsk : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Donetsk : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Kharkiv : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Kyiv : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Lutsk : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Lviv : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Sumy : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Uzhgorod : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Zaporizzhya : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
United Kingdom
London : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Rhyl : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
United States
